Amgen Price Target Raised to $465.00/Share From $405.00 by Citigroup

What happened

Citigroup raised its price target for Amgen to $465.00 per share from $405.00 per share. The article also says Citigroup maintained its Neutral rating on Amgen. It provides no explanation for the target change or further details about the analyst’s reasoning.

Confirmed

Global impact / market context

A higher price target signals that Citigroup now sees more potential value in Amgen shares than its earlier target implied, while the unchanged Neutral rating shows it did not upgrade its overall stance. The article gives no reasons, so investors cannot assess what business assumptions changed.

Analyst inference

The report contains only the target adjustment and confirmation of a Neutral rating; it gives no forecast, financial results, or explanation tied to Amgen’s business. Without that context, the change alone does not show whether expected revenue, costs, or future profits drove the higher target.

Analyst inference

What to watch

1. Check for a later explanation from Citigroup specifying whether its assumptions about Amgen’s revenue, costs, or expected profits changed alongside the target. Analyst inference
2. Watch for any change in Citigroup’s Neutral rating; a rating change would indicate a different overall view, beyond the higher price target. Analyst inference
3. Compare future company results and guidance with the assumptions Citigroup eventually provides, if any, to judge whether the higher target has business support. Analyst inference

Evidence

• Original source link unavailable